Janssen Pharmaceuticals, Inc.

Novartis Ag

Glaxosmithkline Biologicals Sa

Francesco Doro

Janik Adriaansen

Wouter Frank Tonnis

Olga Labovitiadi

Guido Grandi

Manmohan Singh

Nathalie Norais

Domenico Maione

Siddhartha Jain

David Skibinski

Simona Cianetti

Sabrina Liberatori

Derek Thomas O'HAGAN

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are describe.

ExPEC glycoconjugate vaccine formulations

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are described.

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containingantigen polysaccharide covalently bound to a exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are described.

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Compounds and compositions as TLR activity modulators

The invention provides protective antigens for Group Bhypervirulent strains. The fragments are useful in vaccine compositions to induce protection against, particularly against hypervirulent strains.

Growing community of inventors

Siena, Italy

Francesco Doro